Replies to post #780832 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Interesting tech. Trying to make the models used in pre-clinical lab work more accurately reflect the human immune system. Maybe can help in development of next gen immuno-onc agents.

Kind of surprised though you linked a paper this critical of DCVax-L.

While T cell-mediated approaches, including immune checkpoint inhibitors, DCVax, and CAR-T therapies, have shown significant promise in other cancers, there has been limited success with these strategies in glioblastoma (5)

With the reference citation discussing the -L P3 concluding with this sentence:

However, these survival data should be interpreted with caution considering the high crossover rate, a shift in the primary endpoint from PFS to OS, and an inappropriate selection of external controls.

Didn't this message board already dismiss Immunotherapy for glioblastoma: current state, challenges, and future perspectives as being an attack by the evil side?